Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma

被引:21
作者
Moore, JD
Dezube, BJ
Gill, P
Zhou, XJ
Acosta, EP
Sommadossi, JP
机构
[1] Univ Alabama, Birmingham, AL 35294 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Norris Canc Hosp, Los Angeles, CA 90033 USA
关键词
angiogenesis; pharmacokinetics; metabolism; TNP-470; Kaposi's sarcoma; mass spectrometry;
D O I
10.1007/s002800000149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacokinetics of TNP-470 and its major metabolites were investigated in AIDS patients enrolled in a phase I dose escalation trial for the treatment of Kaposi's sarcoma. The patients received TNP-470 by I-h intravenous infusion in dose cohorts of 10, 20, 30, 40, 50 and 70 mg/m(2). The parent drug and metabolites, MII and MIV, were measured by high-performance liquid chromatography/mass spectrometry (HPLC/MS) in plasma samples collected during and out to 168 h after the beginning of the infusion. Both metabolites were detected ill all patients' plasma, while the parent drug was undetectable at time-points as early as 5 mill after the end of infusion for some patients. A large interpatient variability of pharmacokinetic parameters among the dosing cohorts was observed for TNP-470, with a mean (+/- SD) plasma elimination half-life (t(1/2)) of 0.06 +/- 0.04 h, plasma clearance (CL) of 1487 +/- 1216 l/h and an area under the concentration versus time curve (AUC) of 49.9 +/- 35.8 ng/ml . h. Time to maximum plasma concentration (Tmax) typically occurred before the end of the infusion. The predominant plasma metabolite was MII with a t(1/2) of 1.21 +/- 0.43 h, AUC of 1226 +/- 2303 l/h and a Tmax occurring between 5 and 15 min after infusion. The reported active metabolite MIV had a t(1/2) of 0.24 +/- 0.13 h, AUC of 24.9 +/- 32.6 ng/ml . h and a Tmax occurring between the midpoint of the infusion and 15 min after infusion. The parent drug was undetectable by HPLC/MS/MS in urine samples collected and pooled between 0-6 and 6-24 h from the beginning of drug administration. Metabolite MIV was present in the 0-6-h urine pool of two patients enrolled in the highest dosing cohorts, equivalent to 0.4% of the administered dose. Metabolite MII was present in all 0-6-h samples analyzed and represented 1.12 +/- 0.9% of the administered dose. Renal clearance (CLR) for MII was 140 +/- 70 ml/h.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 27 条
[1]  
ABE J, 1994, CANCER RES, V54, P3407
[2]  
ANTOINE N, 1994, CANCER RES, V54, P2073
[3]   The epidemiology of AIDS-related neoplasms [J].
Biggar, RJ ;
Rabkin, CS .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1996, 10 (05) :997-&
[4]   THE COMBINATION OF ANTIANGIOGENIC AGENTS TO INHIBIT PRIMARY TUMOR-GROWTH AND METASTASIS [J].
BREM, H ;
GRESSER, I ;
GROSFELD, J ;
FOLKMAN, J .
JOURNAL OF PEDIATRIC SURGERY, 1993, 28 (10) :1253-1257
[5]   Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys [J].
CrettonScott, E ;
Placidi, L ;
McClure, H ;
Anderson, DC ;
Sommadossi, JP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (02) :117-122
[6]   Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group Study [J].
Dezube, BJ ;
Von Roenn, JH ;
Holden-Wiltse, J ;
Cheung, TW ;
Remick, SC ;
Cooley, TP ;
Moore, J ;
Sommadossi, JP ;
Shriver, SL ;
Suckow, CW ;
Gill, PS .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1444-1449
[7]  
FIGG VD, 1993, J CHROMATOGR B, V652, P187
[8]  
Figg WD, 1997, PHARMACOTHERAPY, V17, P91
[9]   SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH [J].
INGBER, D ;
FUJITA, T ;
KISHIMOTO, S ;
SUDO, K ;
KANAMARU, T ;
BREM, H ;
FOLKMAN, J .
NATURE, 1990, 348 (6301) :555-557
[10]  
KAMEI S, 1993, J PHARMACOL EXP THER, V264, P469